Clinically, midostaurin has shown efficacy in advanced SM patients regardless of KIT mutation status—the pivotal trial included a small subset of D816V-negative cases and still achieved ~60% response rates overall [9,37]. This evidence concerns the gene KIT and systemic mastocytosis.